While we do not deny the uncertainties and risks associated with artificial intelligence (pricing pressures, organisational change, etc.), we remain constructive on this issue, given the significant volume opportunities in prospect for the sector with the integration of agentic AI. Moreover, improving growth momentum in 2026 should reduce pressure on sector valuations (discount >30% vs Stoxx 600 vs a premium of 10% four years ago). On this basis, we have upgraded Bechtle (Outperform vs Neutral),...
Sans nier les incertitudes et risques liés à l’IA (pressions tarifaires, changements organisationnels, etc.), nous restons constructifs sur cette thématique tant les opportunités de volumes autour de l’intégration de l’IA agentique sont importantes pour le secteur. D’autant plus que l’amélioration de la dynamique de croissance en 2026 devrait permettre de réduire la pression sur les valorisations du secteur (décote >30% vs Stoxx 600 contre une prime de 10% il y a 4 ans). Dans ce contexte, nous r...
CARBIOS : half-year report on the liquidity contract entrusted to Natixis ODDO BHF and notice of suspension PRESS RELEASE Shares concerned: Carbios (ISIN code: FR0011648716)Market concerned: Euronext Growth Paris Clermont-Ferrand, France, January 20, 2026 (6:00 pm CET). today presents the half-year report on the liquidity contract signed with Natixis ODDO BHF on June 12, 2020, and announces its suspension, effective January 19, 2026, as the liquidity of the shares is now deemed satisfactory. As of January 19, 2026, after market close, the resources in the liquidity account amounted to 1...
CARBIOS : Bilan semestriel du contrat de liquidité confié à Natixis ODDO BHF et annonce de sa suspension Titre concerné : CARBIOS (code ISIN FR0011648716)Marché concerné : Euronext Growth Paris Clermont-Ferrand (France), le 20 janvier 2026 (18h00 CET). présente le bilan semestriel du contrat de liquidité conclu avec Natixis ODDO BHF en date du 12 juin 2020 et annonce sa suspension, à compter du 19 janvier 2026, compte-tenu de la liquidité du titre qui est aujourd’hui jugée satisfaisante. Les moyens qui figuraient au compte de liquidité en date du 19 janvier 2026, après clôture des marché...
A director at Abivax sold 1,000,000 shares at 122.334USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Abivax Provides 2026 Corporate Outlook Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD spaceABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found no new safety signals with over 80% of participants having completed the 44-week double blind maintenance trialABTECT-UC Phase 3 maintenance topline results expected late Q2 2026, with a subsequent US regulatory filing planned for late 2026ENHANCE-CD ...
Abivax to be Added to Nasdaq Biotechnology Index Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. Didie...
CARBIOS maintains its commitment to build the Longlaville plant and adjusts its timeline CARBIOS reaffirms its ambition to pursue the Longlaville plant construction project and postpones the timeline by three-month.The plant construction project is supported by: Pre-commercialization contracts covering close to 50% of the production capacity of the future industrial site in Longlaville.Significant progress in structuring the additional financing required to restart the project.Secured public funding of €42.5 million. A small portion1 of the financing still needs to be secured before the p...
CARBIOS maintient son objectif de construction de l’usine de Longlaville avec un calendrier ajusté CARBIOS réaffirme son ambition de poursuivre le projet de construction de l’usine à Longlaville en décalant le calendrier prévisionnel de trois mois.Le projet de construction de l’usine est aujourd’hui conforté par : Des contrats de pré-commercialisation couvrant près de 50 % de la capacité de production du futur site industriel de Longlaville.Des avancées significatives dans la structuration des financements complémentaires nécessaires au redémarrage du projet.Des aides publiques confirmées à...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.